AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 16924336
Drug: Passive topical
RxNorm normalized name: RESPIRATORY TUBE 22MM PASSIVE R#1147378
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Passive topical application of Carisolv + SRP
Trial: 16924336
Drug: Active topical
RxNorm normalized name: Similasan Arnica Active Topical Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active topical application of Carisolv + SRP
Trial: 16924336
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of Carisolv + SRP + 24% EDTA
Trial: 14714579
Drug: Imidapril (5‐10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imidapril (5‐10 mg/day) or benazepril (10‐20 mg/day) for 6 weeks
Trial: 10986059
Drug: Intensive chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive chemotherapy including multiple, prolonged courses of corticosteroid (dexamethasone)
Trial: 3534246
Drug: Antidepressant treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant treatment over 12 weeks (6-week standard trial followed by 6-week continuation for responders)
Trial: 31547949
Drug: Splint therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Splint therapy with ultrasound‐guided arthrocentesis
Trial: 31547949
Drug: Splint therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Splint therapy with low‐level laser therapy
Trial: 20565314
Drug: Unit-dose pipettes
RxNorm normalized name: colloidal oatmeal
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unit-dose pipettes
Trial: 18391094
Drug: Stepped care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stepped care treatment with chlorthalidone and atenolol (n=2365)
Trial: 12866040
Drug: Aspirin exclusively
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin exclusively
Trial: 12866040
Drug: Non-aspirin NSAIDs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-aspirin NSAIDs exclusively (e.g., ibuprofen)
Trial: 12866040
Drug: Both aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Both aspirin and non-aspirin NSAIDs
Trial: 12866040
Drug: No use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No use of aspirin or other non-aspirin NSAIDs
Trial: 10819336
Drug: Zanamivir (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zanamivir (10 mg, inhaled, twice daily for 5 days)
Trial: 8887036
Drug: Glycyrrhizin (GL)
RxNorm normalized name: glycyrrhizinate
DrugBank: Glycyrrhizic acid (DB13751)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glycyrrhizin (GL) given intravenously at a dose of 40 ml (0.2% solution) daily for 4 consecutive weeks.
Trial: 24858506
Drug: Forest therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Forest therapy (viewing a real forest landscape for 15 min)
Trial: 19853510
Drug: Lenalidomide 25
RxNorm normalized name: lenalidomide 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenalidomide 25 mg on days 1-21 plus dexamethasone 40 mg on days 1-4, 9-12, and 17-20 of a 28-day cycle (high dose)
Trial: 19853510
Drug: Lenalidomide 25
RxNorm normalized name: lenalidomide 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenalidomide 25 mg on days 1-21 plus dexamethasone 40 mg on days 1, 8, 15, and 22 of a 28-day cycle (low dose)
Trial: 19853510
Drug: Low-dose dexamethasone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose dexamethasone group
Trial: 19853510
Drug: High-dose dexamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose dexamethasone group
Trial: 6781586
Drug: High-dose regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose regimen
Trial: 19853510
Drug: Low-dose regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose regimen
Trial: 16197655
Drug: Milnacipran (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milnacipran (50 mg/day increasing to 100 mg/day after 1 week)
Trial: 14499730
Drug: Aspirin and
RxNorm normalized name: Aspirin and Caffeine Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin and heparin
Trial: 8707167
Drug: Standard unfractionated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard unfractionated heparin (Ca-heparin, 3 x 5,000 U)
Trial: 1867903
Drug: Contract condition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contract condition with co-worker-delivered reminders, prompting at least once a month for six months, plus mailed prompts monthly.
Trial: 1867903
Drug: Control condition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control condition with mailed prompts monthly.
Trial: 25647757
Drug: R-L+ stimulation
RxNorm normalized name: L-methionine-S,R-sulfoximine
DrugBank: Methionine sulfoximine (DB14103)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-L+ stimulation (anodal stimulation of left PPC)
Trial: 25647757
Drug: R+L- stimulation
RxNorm normalized name: L-methionine-S,R-sulfoximine
DrugBank: Methionine sulfoximine (DB14103)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R+L- stimulation (anodal stimulation of right PPC)
Trial: 10990103
Drug: Enteral plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteral plus parenteral nutrition (treatment group)
Trial: 8741021
Drug: EGb 761
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EGb 761 (240 mg daily)
Trial: 1331493
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate 200 mg kg‐1
Trial: 1331493
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate 300 mg kg‐1
Trial: 1331493
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate 400 mg kg‐1
Trial: 1331493
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate 500 mg kg‐1
Trial: 1331493
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate 100 mg kg‐1
Trial: 1331493
Drug: Placebo (CaCO3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (CaCO3 500 mg kg‐1)
Trial: 4019271
Drug: Delayed 252Cf
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed 252Cf implant therapy
Trial: 4019271
Drug: Early 252Cf
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early 252Cf implant therapy
Trial: 31115845
Drug: Participants in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in the SELECT BC trial receiving either S-1 or taxane as first-line treatment.
Trial: 31115845
Drug: Non-participants who
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-participants who received the same chemotherapy (S-1 or taxane) after declining participation.
Trial: 26636418
Drug: P‐3074 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P‐3074 1 mL (2.275 mg) applied to the scalp once a day (o.d.)
Trial: 26636418
Drug: P‐3074 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P‐3074 1 mL (2.275 mg) applied to the scalp twice a day (b.i.d.)
Trial: 26636418
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg oral tablet of finasteride once a day (o.d.)
Trial: 24484178
Drug: rF-B7.1 or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rF-B7.1 or rF-TRICOM (3.7×10(7) or 3.7×10(8) plaque-forming units) administered by intralesional injection every 4 weeks
Trial: 19857185
Drug: Therapeutic cancer
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic cancer vaccines (various types including antigen-presenting-cell-based, vector-based, and whole tumor cell vaccines)
Trial: 16094110
Drug: Topical lysine-aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical lysine-aspirin (16 mg every 48 hours for 6 months)
Trial: 7564036
Drug: Warfarin (anticoagulant)
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Warfarin (anticoagulant) alone for 21 days
Trial: 7564036
Drug: Combined use
RxNorm normalized name: CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined use of anticoagulants and antiplatelet agents
Trial: 1793024
Drug: Gold treatment
RxNorm normalized name: GLYCERIN 0.01 g in 1 mL TOPICAL LIQUID [BURZANGMURY GOLD TREATMENT]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gold treatment
Trial: 1793024
Drug: Both gold
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both gold and MTX treatment
Trial: 31782786
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of glucocorticoids (GCs) and cyclophosphamide (CYC)
Trial: 31474526
Drug: Health care
RxNorm normalized name: Health Care Lancing Device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Health care practitioner counseling on medication disposal
Trial: 22926533
Drug: Oxygen pressure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen pressure injection (OPI) device during MAL‐PDT
Trial: 17699970
Drug: 750 ml
RxNorm normalized name: ALCOHOL 750 mL in 1 L TOPICAL GEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 ml spacer with valve
Trial: 17699970
Drug: 165 ml
RxNorm normalized name: ALCOHOL 165 mL in 250 mL TOPICAL GEL [INSTANT HAND SANITIZER]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 165 ml spacer with valve
Trial: 17699970
Drug: 250 ml
RxNorm normalized name: TPN Bag 250 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 ml spacer without valve
Trial: 17699970
Drug: 1000 ml
RxNorm normalized name: TPN Bag 1000 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 ml indigenously made spacer without valve
Trial: 17699970
Drug: 500 ml
RxNorm normalized name: TPN Bag 500 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 ml indigenously made spacer without valve
Trial: 15601653
Drug: Intravenous quinine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous quinine followed by oral Malarone
Trial: 15601653
Drug: Intravenous quinine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous quinine followed by oral quinine
Trial: 6775518
Drug: High nitrogen
RxNorm normalized name: Isosource High Nitrogen Liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High nitrogen (N) intravenous nutritional regimen
Trial: 26969422
Drug: Metal injection
RxNorm normalized name: menthone 1,2-glycerol ketal, (-)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metal injection moulding (MIM) brackets
Trial: 19074978
Drug: Cognitive-behavioral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral treatment focusing solely on eating disorder features
Trial: 19074978
Drug: Complex cognitive-behavioral
RxNorm normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complex cognitive-behavioral treatment addressing mood intolerance, clinical perfectionism, low self-esteem, or interpersonal difficulties
Trial: 19074978
Drug: Waiting list
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Waiting list control condition (8-week period before treatment)
Trial: 11286443
Drug: Various treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various treatments for cluster headaches; specific interventions not detailed; no dosage or duration mentioned.
Trial: 29766701
Drug: Topical daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical daily application of a lotion containing N1‐methylspermidine and Sandalore
Trial: 24281004
Drug: Dose-escalated weekly
RxNorm normalized name: selinexor
DrugBank: Selinexor (DB11942)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dose-escalated weekly paclitaxel (80-120 mg/m²)
Trial: 24281004
Drug: Standard-dose weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose weekly paclitaxel (80 mg/m²)
Trial: 22322126
Drug: 4% chlorhexidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% chlorhexidine (CHX) solution applied to the umbilical cord at birth and once daily for up to 14 days along with soap and educational messages promoting handwashing.
Trial: 18939344
Drug: Topical Cyclosporin
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Cyclosporin A (Restasis) with intensive prednisolone acetate
Trial: 12110996
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg pyridostigmine bromide (PB)
Trial: 12110996
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg pyridostigmine bromide (PB)
Trial: 31899792
Drug: Gastric atrophy
RxNorm normalized name: gastric mucins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gastric atrophy (defined as a serum level of pepsinogen I <55 μg/L)
Trial: 31899792
Drug: Gastric atrophy
RxNorm normalized name: gastric mucins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gastric atrophy and poor oral health interaction
Trial: 26944326
Drug: Neostigmine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine (50 μg/kg) plus atropine (15 μg/kg)
Trial: 22639053
Drug: Fixed-schedule induction
RxNorm normalized name: Humalog Mix Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-schedule induction therapy
Trial: 22639053
Drug: Individualized induction
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized induction therapy
Trial: 20029377
Drug: 200 g
RxNorm normalized name: PEG-200 GLYCERYL STEARATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 g fructose daily for 2 weeks
Trial: 19029205
Drug: Pravastatin (cholesterol-lowering
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin (cholesterol-lowering drug)
Trial: 12211225
Drug: Cetrorelix acetate
RxNorm normalized name: Cetrorelix Acetate
DrugBank: Cetrorelix (DB00050)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cetrorelix acetate (CET/glu, dose: 10 mg peptide base)
Trial: 12211225
Drug: Cetrorelix acetate
RxNorm normalized name: Cetrorelix Acetate
DrugBank: Cetrorelix (DB00050)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cetrorelix acetate (CET/wat, dose: 10 mg peptide base)
Trial: 12211225
Drug: Cetrorelix acetate
RxNorm normalized name: Cetrorelix Acetate
DrugBank: Cetrorelix (DB00050)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cetrorelix acetate (CET/glu, dose: 5 mg peptide base)
Trial: 10768735
Drug: Zafirlukast tablets
RxNorm normalized name: Zafirlukast Tablets
DrugBank: Zafirlukast (DB00549)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zafirlukast tablets (Accolate) 20 mg b.i.d.
Trial: 10768735
Drug: Inhaled beclomethasone
RxNorm normalized name: beclomethasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled beclomethasone dipropionate (BDP) 100 or 200 microg b.i.d.
Trial: 1354618
Drug: Bunazosin 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bunazosin 2.0 mg
Trial: 18538469
Drug: Degarelix 200
RxNorm normalized name: Degarelix
DrugBank: Degarelix (DB06699)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Degarelix 200 mg initial dose
Trial: 18538469
Drug: Degarelix 240
RxNorm normalized name: Degarelix
DrugBank: Degarelix (DB06699)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Degarelix 240 mg initial dose
Trial: 12442064
Drug: Insulin twice
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin twice daily (premixed combination of regular human and NPH insulin)
Trial: 12442064
Drug: Bedtime NPH
RxNorm normalized name: Buckley's Bedtime Formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bedtime NPH insulin combined with daytime sulphonylurea (combination group)
Trial: 10616949
Drug: Psychological therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychological therapy (individual cognitive behavioural therapy and applied relaxation)
Trial: 10616949
Drug: Psychological therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychological therapy (aggregate data across types of treatment)
Trial: 10616949
Drug: Psychological therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychological therapy (12 of the 20 treatment conditions)
Trial: 7853954
Drug: Dantrolene (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dantrolene (3 days treatment)
Trial: 2006594
Drug: Saline +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline + Propofol 2.5 mg.kg‐1
Trial: 2006594
Drug: Alfentanil 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil 20 micrograms.kg‐1 + Propofol 2.5 mg.kg‐1
Trial: 2006594
Drug: Alfentanil 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil 30 micrograms.kg‐1 + Propofol 2.5 mg.kg‐1
Trial: 2006594
Drug: Alfentanil 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil 30 micrograms.kg‐1 + Propofol 2.5 mg.kg‐1 (Control for Pain)
Trial: 6844366
Drug: Timolol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timolol (10 mg)/Hydrochlorothiazide (25 mg)/Amiloride (2.5 mg) preparation
Trial: 6844366
Drug: Full explanation
RxNorm normalized name: Full Marks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full explanation for the change in therapy
Trial: 6844366
Drug: Simple notification
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simple notification of treatment change
Trial: 30443679
Drug: Interferon alpha
RxNorm normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alpha (IFN‐α) administered subcutaneously at a dosage of 15,000 Units for three consecutive days following myocardial infarction in a rat model
Trial: 11093698
Drug: Oxygen administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen administration during walks
Trial: 9351876
Drug: Pamidronate therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamidronate therapy (60 mg every 3 weeks, administered 4 times)
Trial: 8214731
Drug: morphine 2
RxNorm normalized name: apomorphine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: morphine 2 mg/fentanyl 50 micrograms
Trial: 8214731
Drug: morphine 2
RxNorm normalized name: apomorphine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: morphine 2 mg/fentanyl 100 micrograms
Trial: 8214731
Drug: morphine 4
RxNorm normalized name: morphine 4 mg/mL injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: morphine 4 mg/fentanyl 50 micrograms
Trial: 8214731
Drug: morphine 4
RxNorm normalized name: morphine 4 mg/mL injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: morphine 4 mg/fentanyl 100 micrograms
Trial: 31414957
Drug: Acute xenon
RxNorm normalized name: xenon
DrugBank: Xenon (DB13453)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute xenon inhalation (30% FiXe for 20 min, 50% FiXe for 5 min, 70% FiXe for 2 min)
Trial: 31414957
Drug: Chronic xenon
RxNorm normalized name: xenon
DrugBank: Xenon (DB13453)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chronic xenon inhalation (70% FiXe for 2 min on 7 consecutive days)
Trial: 31414957
Drug: 4 wk
RxNorm normalized name: Rheumatrex Dose Pack 12, 4 Wk Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 wk of xenon inhalation (Phase II)
Trial: 17311944
Drug: combination muesli
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: combination muesli
Trial: 14967379
Drug: Raloxifene (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene (60 mg daily)
Trial: 7946164
Drug: Intravenous nitroprusside
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous nitroprusside (SNP)
Trial: 3284065
Drug: Aza (2.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aza (2.1 mg/kg/d) plus MP (3.6 mg/kg/d tapered to 0.5 mg/kg/d by day 15)
Trial: 3284065
Drug: CsA (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CsA (10 mg/kg/d tapered to 8 mg/kg/d by day 28)
Trial: 3284065
Drug: CsA (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CsA (10 mg/kg/d tapered to 8 mg/kg/d by day 28) plus MP (3.6 mg/kg/d tapered to 0 mg/kg/d by day 9)
Trial: 30099395
Drug: Morita Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morita Therapy plus treatment as usual (TAU)
Trial: 11078174
Drug: Cortisol (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cortisol (oral administration for 2 or 5 days)
Trial: 11078174
Drug: Placebo (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (oral administration for 2 or 5 days)
Trial: 1400058
Drug: 20 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 micrograms of intranasal DDAVP
Trial: 30716525
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy (RT) with a brain target volume receiving focal radiation therapy in fractions of 1.8 Gy to a total of 50.4 Gy
Trial: 26395351
Drug: Daily tooth
RxNorm normalized name: Sus scrofa tooth preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily tooth brushing with 500 ppm fluoride toothpaste, supervised by specially trained dental nurses.